Astellas.com - SEO Check

Jetzt kostenlos registrieren! PDF Export
Übersicht der SEO Analyse
Metaangaben
75% 
Seitenqualität
79% 
Seitenstruktur
79% 
Verlinkung
85% 
Server
95% 
Externe Faktoren
100% 
SEO Score
Antwortzeit
1,86 s
Dateigröße
84,90 kB
Wörter
1056
Medien
18
Anzahl Links
203 Intern / 4 Extern

To-do Liste mit SEO Optimierungen

Meta-Angaben im HTML

Titel
(Extrem wichtig)
Astellas Home page | Astellas Pharma Inc.
Die Länge des Titels ist optimal. (383 Pixel von maximal 580 Pixel Länge)
Es gibt keine Wortwiederholungen im Titel.
Meta-Description
(Extrem wichtig)
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.
Die Meta-Description ist zu lang. (1192 Pixel von maximal 1000 Pixel) Jetzt optimieren
Crawlbarkeit
(Extrem wichtig)
Es gibt keine Probleme beim Zugriff auf die Webseite.
Canonical Link
(Wichtig)
https://www.astellas.com/en
Der angegebene Canonical Link verweist auf eine andere URL.
Sprache
(Wenig wichtig)
Im Text erkannte Sprache: en
Im HTML angegebene Sprache: en
Serverstandort: Vereinigte Staaten von Amerika
Die Sprache wird im HTML Code wie folgt angegeben: en
Alternate/Hreflang Links
(Wenig wichtig)
Die angegebenen Alternate Links sind fehlerfrei.
Weitere Metatags
(Wenig wichtig)
Es gibt keinen rel next Meta Tag auf der Seite.
Es gibt keinen rel prev Meta Tag auf der Seite.
Domain
(Wenig wichtig)
Die Domain ist keine Subdomain.
Die Länge der Domain ist gut.
Die Domain enthält keine Umlaute.
Seiten URL
(Wenig wichtig)
In der URL wurden keine Parameter entdeckt.
In der URL wurde keine Session ID entdeckt.
Die URL hat nicht zu viele Unterverzeichnisse.
Zeichensatzkodierung
(Wenig wichtig)
Die Angaben zur Zeichensatzkodierung (UTF-8) sind fehlerfrei.
Doctype
(Nice to have)
Die Doctype Angabe HTML 5 ist korrekt angegeben.
Die Doctype Angabe befindet sich an erster Stelle im HTML-Code.
Favicon
(Nice to have)
Das Favoriten Icon (Favicon) ist korrekt verlinkt.

Meta Tags

NameWert
descriptionAstellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.
thumbnailhttps://www.astellas.com/en/jp/sites/all/themes/astellas/logo.svg
GeneratorDrupal 10 (https://www.drupal.org)
MobileOptimizedwidth
HandheldFriendlytrue
viewportwidth=device-width, initial-scale=1.0
langen
twitter:cardsummary_large_image
twitter:titleTOP
twitter:imagehttps://www.astellas.com/en/sites/all/themes/astellas/astellas_logo_1200-630.jpg
og:titleAstellas Home page | Astellas Pharma Inc.
og:descriptionAstellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.
og:imagehttps://www.astellas.com/en/sites/all/themes/astellas/astellas_logo_1200-630.jpg
charsetutf-8

Analysiere jetzt kostenlos bis zu 1.000 Unterseiten von astellas.com!

Kostenlos Testen
Die Nutzung des Basis Accounts ist zeitlich unbegrenzt möglich

Seitenqualität

Inhalt
(Extrem wichtig)
Einige Wörter aus dem Seitentitel werden nicht im Text bzw. Inhalt der Seite verwendet
Der Inhalt ist mit 1056 Wörtern in Ordnung.
Der Text besteht zu 24% aus Füllwörtern.
Im Text befindet sich eine Aufzählung, dies deutet auf eine gute Textstruktur hin.
Es wurden 11 Fließtextblöcke auf der Seite gefunden.
Es wurden keine Platzhalter Texte bzw. Bilder gefunden.
Es befinden sich keine Duplikate auf der Seite.
Die durchschnittliche Satzlänge ist mit 18.5 Wörtern gut.
Frames
(Extrem wichtig)
Die Seite hat kein Frameset.
Mobile
(Wenig wichtig)
Es ist kein Apple-Touch Icon angegeben.
Der angegebene Viewport (width=device-width, initial-scale=1.0) ist korrekt.
Bold- und Strongtags
(Wenig wichtig)
Die Nutzung von Strong- und Bold-Tags ist optimal. Wir empfehlen für diese Webseite die Verwendung von bis zu 21 Tags.
Bilder Optimierung
(Wenig wichtig)
Alle gefundenen Bilder haben Alt-Attribute. (Alternativer Bild Text)
Soziale Vernetzung
(Nice to have)
Es befinden sich wenige Social-Sharing Möglichkeiten auf der Seite. Mit Plugins zum Teilen kann die Reichweite der Seite in sozialen Netzwerken erhöht werden.
Zusätzliches Markup
(Nice to have)
Es wurde kein zusätzliches Markup gefunden.
HTTPS
(Wenig wichtig)
Die Seite verwendet HTTPS um Daten sicher zu übertragen.
Alle eingebundenen Dateien werden ebenfalls über HTTPS ausgeliefert.

Medienliste

URLALT-AttributeTitel
/themes/custom/astellas_v2/logo.svgAstellas Pharma Inc.Astellas Pharma Inc.
/sites/all/themes/astellas/logo.svglogo
...er_Integrated-Report-2024_1920x523px.pngIntegrated Report 2024
...der_Integrated-Report-2024_960x540px.pngIntegrated Report 2024
...image/2024-10/Story_960-540px_topics.jpgLeading the Charge in Oncology
..._banner_image/2024-10/600_300_topics.jpgFinancial Results for Q1/FY2024
...er_image/2023-05/From the CEO_600300.pngFrom the CEO
...lated_banner_image/2022-10/top_about.pngAbout us
...ted_banner_image/2022-10/top_r-and-d.pngR & D Strategy
...ner_image/2022-10/top_sustainability.pngAstellas and Sustainability
...mage/2022-10/top_partnering_20221017.pngPartnering with Astellas
...mage/2022-10/top_partnering_20221017.pngPartnering with Astellas
...sub_menu_image/2022-10/top_investors.pngInvestor Relations
.../sub_menu_image/2022-10/top_linkedin.pngLinkedIn
...ll/themes/astellas/images/logo_white.svgfooter logo
...all/themes/astellas/images/solgan_en.svgfooter solgan
...les/bxbito15231/files/linkedin_small.pngLinkedin Logo
...les/bxbito15231/files/youtube_footer.pngYoutube Logo

Seitenstruktur

H1 Überschrift
(Extrem wichtig)
Es ist keine H1-Überschrift definiert.
Überschriften
(Wichtig)
Die Überschriftenstruktur ist fehlerhaft. Es sollte keine Hierarchie (H1-H6) ausgelassen werden.

Überschriftenstruktur

Überschriften HierarchieInhalt
H2 Stakeholders menu
H2 Common header menu
H2 Integrated Report 2024
H2 Leading the Charge in Oncology
H2 Financial Results for Q1/FY2024
H2 From the CEO
H2 About us
H2 R & D Strategy
H2 Sustainability
H2 Partnering with Astellas
H2 Investor Relations
H2 Astellas Pharma’s official LinkedIn
H2 Modern Slavery Act 2015
H2 Contact for Potential Acquisition of Astellas’ R＆D programs.
H2 Bottom footer menu
Einige der Linktexte der internen Links sind zu lang.
Einige der Linktexte wiederholen sich.
Die Anzahl an internen Links ist ok.
Alle internen Links haben keine dynamischen Parameter.
Es befinden sich 4 externe Links auf der Seite.

Gefundene Links auf dieser Seite

LinkAttributeLinktext
https://www.astellas.com/enIMG-ALT Astellas Pharma Inc.
https://www.astellas.com/en/aboutAbout
/en/investors/strategic-planCorporate Strategic Plan 2021 Corporate Strategic Plan 2021 (CSP2021) maps the next five years of our journey. Read More
/en/about/messageFrom the CEO
/en/about/philosophyPhilosophy
/en/about/charter-of-corporate...Astellas Charter of Corporate Conduct, Group Code of Conduct
/en/about/visionVISION
/en/about/corporate-informationAt a Glance
/en/about/subsidiaries-and-loc...Subsidiaries & Locations
/en/about/our-businessOur Business
/en/about/main-productsMain Products
/en/about/historyHistory
/en/about/managementManagement
/en/about/board-of-directorsBoard of Directors
/en/about/top-managementGlobal Management Structure
/en/about/governanceCorporate Governance Materials
/en/about/risk-managementRisk Management
/en/about/policies-and-positio...Policies & Position Statements
/en/about/ethics-complianceEthics & Compliance
/en/about/structure-to-promoteStructure to Promote Ethics and Compliance
/en/about/primary-areas-of-focusPrimary Areas of Focus
/en/about/elements-of-astellas...Elements of Astellas’ Global Ethics & Compliance Program
/en/about/enhancing-and-sustai...Enhancing and Sustaining an Ethical and Compliant Culture at Astellas
/en/about/astellas-compliance-...Astellas awarded Compliance Leader Verification™
/en/innovationInnovation
/en/innovationInnovation We pursue cutting-edge science to continuously provide innovative treatment options. Read More
/en/innovation/rd-strategyR＆D Strategy
/en/innovation/drug-researchDrug Research
/en/innovation/pipelineMajor Pipeline
/en/innovation/clinical-trialsClinical Trials
/en/innovation/investigator-sp...Investigator Sponsored Research
/en/innovation/grants-for-educ...Grants for Education and General Research
/en/innovation/grants-for-educ...Grants to HCOs to Support HCP Attendance at Congresses
/en/innovation/areas-of-interestAreas of Interest
/en/innovation/primary-focus-g...Genetic Regulation
/en/innovation/primary-focus-i...Immuno-Oncology
/en/innovation/primary-focus-b...Blindness & Regeneration
/en/innovation/primary-focus-t...Targeted Protein Degradation
/en/innovation/primary-focus-c...Immune Homeostasis
/en/innovation/exploratory-res...Bispecific Immune Cell Engager
/en/innovation/engineered-phag...Engineered Phage Therapy
/en/innovation/direct-reprogra...Direct Reprogramming
/en/innovation/innate-immune-r...Innate Immune Regulation
/en/innovation/circadian-rhyth...Circadian Rhythm Regulation
/en/innovation/cell-therapyCell Therapy
/en/innovation/digital-transfo...Digital Transformation
/en/innovation/dx-initiatives-...DX Initiatives Throughout the Value Chain
/en/innovation/data-informatio...Data, Information and Advanced Analytics
/en/innovation/rx-plusNew Healthcare Solutions Beyond Medicine (Rx+®)
/en/innovation/leading-programsLeading Programs
/en/innovation/investigational...Investigational Near-Infrared Fluorescence Imaging Agent
/en/innovation/clinically-rele...Clinically Relevant Holistic Solutions Mobile Healthcare Application
/en/innovation/new_digital_the...New Digital Solution for Heart Failure Patients on the Horizon
/en/innovation/open-innovationOpen Innovation in Drug Discovery Research
/en/innovation/open-innovation...Our Philosophy of Open Innovation
/en/innovation/open-innovation...SakuLab-Tsukuba
/en/innovation/open-innovation...TME iLab
/en/innovation/open-innovation...SakuLab-Cambridge MA
/en/partneringSubdomain Partnering
/en/investorsInvestors
/en/investorsInvestor Relations You can access to IR related information including IR Library, Financial Information, Corporate Strategic Plan. Read More
/en/investors/strategic-planCorporate Strategic Plan 2021
/en/investors/integrated-reportIntegrated Report
/en/investors/integrated-repor...Archives
/en/investors/astellas-esg-ini...Astellas’ ESG Initiatives
/en/investors/enhancementAction to Implement Management that is Conscious of Cost of Capital and Stock Price
/en/investors/financial-inform...Financial Information
/en/investors/ir-libraryIR Library
/en/investors/ir-library/busin...Business Results
/en/investors/ir-library/pipelineOverview of R&D Pipeline
/en/investors/ir-library/ir-me...IR Meetings
/en/investors/consolidated-fin...Consolidated Financial Statements and Footnotes
/en/about/governanceTextduplikat Corporate Governance Materials
/en/investors/ir-calendarIR Calendar
/en/investors/stock-rating-inf...Stock & Rating Information
/en/investors/shareholders-mee...Shareholders Meeting
/en/investors/shareholder-returnShareholder Return
/en/investors/current-share-st...Current Share Status
/en/investors/chartChart
/en/investors/ratingsIssuer Rating
/en/investors/analyst-coverageAnalyst Coverage
/en/investors/cautionary-state...Cautionary Statement
/en/investors/individual-inves...Introducing Astellas to Individual Investors
/en/sustainabilitySustainability
/en/sustainability/sustainabil...Sustainability Direction We have set Med-term Priorities, Initiatives, and Our Commitments by FY2025 as for Two pillars and Environmental Sustainability. Rea...
/en/sustainability/our-approachMessage from CEO
/en/sustainability/sustainabil...Sustainability Approach
/en/sustainability/astellas-su...Sustainability Governance
/en/sustainability/materialityKey Issues and Materiality
/en/sustainability/sustainabil...Sustainability Direction
/en/sustainability/sdpisSustainability Direction Performance Indicators (SDPIs)
/en/sustainability/iso26000ISO26000
/en/sustainability/un-developm...Astellas’ SDG Initiatives
/en/sustainability/united-nati...United Nations Global Compact
/en/sustainability/stakeholder...Stakeholder Communications
/en/sustainability/awards-and-...Awards & Recognition
/en/sustainability/access-to-h...Access to Health
/en/sustainability/access-to-h...Access to Health of Astellas
/en/sustainability/access-to-m...Access to Medicines
/en/sustainability/initiatives...Initiatives in Tanzania
/en/sustainability/strengtheni...Healthcare Systems Strengthening
/en/sustainability/program-in-...Program in Mexico
/en/sustainability/program-in-...Program in Dominican Republic
/en/sustainability/program-in-...Program in Peru
/en/sustainability/program-in-...Program in Malaysia
/en/sustainability/development...Development for Schistosomiasis
/en/sustainability/research-ac...Research Activity on Malaria
/en/sustainability/research-ac...Research Activities on NTDs
/en/sustainability/astellas-he...Astellas Healthcare E-city
/en/sustainability/ghit-fundGHIT Fund
/en/sustainability/enrich-the-...Patient Support Activity
/en/sustainability/sustainable...Working together to bring “medical-eco” activities to drug discovery in Japan
/en/sustainability/cncCommitment to healthcare for local communities
/en/sustainability/project-com...Activities of "Project Commune" in FY 2023
/en/sustainability/project-com...Activities of "Project Commune" in FY 2024
/en/sustainability/advancement...Medical Science Advancement
/en/sustainability/astellas-gl...Astellas Global Health Foundation
/en/sustainability/access-to-m...Access to Medicine Index Report
/en/sustainability/environmentEnvironment
/en/sustainability/initiatives...Environment Initiatives
/en/sustainability/environment...EHS Management
/en/sustainability/status-of-o...ISO certification status of Astellas production sites
/en/sustainability/environment...Environmental Action Plan and Compliance
/en/sustainability/measures-to...Climate Change Measures
/en/sustainability/scope-3-emi...Scope 3 emissions (past 3 years)
/en/sustainability/TCFD-disclo...Disclosure based on TCFD
/en/sustainability/breakdown-o...Energy Consumption
/en/sustainability/preserving-...Sustainable Biodiversity
/en/sustainability/preserving-...Biodiversity and Astellas An Enlarged Version
/en/sustainability/the-biodive...The Biodiversity Burden Index and Revenue
/en/sustainability/initiatives...Resource Recycling
/en/sustainability/initiatives...Preventing Pollution
/en/sustainability/further-inf...Further information on PRTR system
/en/sustainability/environment...Environmental Impact of Products and Countermeasures
/en/sustainability/environment...Archive (EHS Report)
/en/sustainability/environment...Environmental Accounting
/en/sustainability/environment...Environment-related Investments and Expenses
/en/sustainability/reporting-c...Reporting coverage, methods
/en/sustainability/socialAstellas and Society
/en/sustainability/our-peopleOur People
/en/sustainability/hr-visionHR Vision, Talent and Organization Management
/en/sustainability/diversity-m...Engagement and Diversity, Equity & Inclusion
/en/sustainability/a-living-wageA living wage
/en/sustainability/occupationa...Occupational Health & Safety
/en/sustainability/promoting-h...Promoting Health Management
/en/sustainability/major-progr...Major Activities and Programs (Japan)
/en/sustainability/sustainabil...Sustainability in Business Practice
/en/sustainability/sustainable...Sustainable Procurement Initiatives
/en/sustainability/research-in...Research Initiatives
/en/sustainability/clinical-de...Clinical Development Initiatives
/en/sustainability/technologic...Technological Development and Production Initiatives
/en/sustainability/distributio...Distribution and Sales Initiatives
/en/sustainability/respect-for...Respect for Human Rights
/en/sustainability/community-e...Community Engagement
/en/sustainability/flyingstarFlying Star Fund
/en/sustainability/changing-to...Employee Contributions to the Local Community
/en/sustainability/governanceGovernance
/en/sustainability/esgESG Data
/en/sustainability/esg-environ...ESG Data Environment
/en/sustainability/esg-socialESG Data Social
/en/sustainability/esg-governanceESG Data Governance
/en/newsroomNews
/en/newsroomNews Room Check the latest news and our people's stories. Read More
https://www.astellas.com/en/newsALL News
/en/storiesOUR STORIES
/en/newsroom/media-libraryMedia Library
/en/partneringTextduplikat Partnering
/en/partnering/partnershipWhy Partner with Astellas
/en/partnering/partnering-teamsPartnering Teams
/en/partnering/testimonies-fro...Testimonies from our Partners
/en/partnering/register-formRegistration Form
/en/careers-at-astellasCareers
/en/suppliersSuppliers
/en/contact-usContact Us
https://www.astellas.com/enIMPORTANT NOTICE
/en/worldwideWORLDWIDE
https://www.astellas.com/enGLOBAL
https://www.astellas.com/jp日本
https://www.astellas.com/Cancel
https://www.astellas.com/Neues Fenster Click here to leave this site.
/en/system/files/8ddc22a762/as...Subdomain Integrated Report 2024 Please check the latest Integrated Report. View more
/en/stories/leading_the_charge...Leading the Charge in Oncology Chief Medical Officer Tadaaki Taniguchi shares insights on how Astellas is advancing oncology with next-generation modalities....
IMG-ALT Leading the Charge in Oncology
/en/investors/ir-library/busin...Financial Results for Q1/FY2024 We announced our financial results for Q1/FY2024 on August 1st. Presentation material, video, and meeting script are availabl...
IMG-ALT Financial Results for Q1/FY2024
/en/about/messageFrom the CEO I will make every effort to navigate Astellas with speed and a sense of urgency that “our patients are waiting.” Read more
IMG-ALT From the CEO
/en/news/29471Oct 04, 2024General News Integrated Report 2024 is now available.
/en/news/29466Oct 02, 2024Stories Leading the Charge in Oncology: How Astellas is Redefining Cancer Treatment
/en/news/29451Sep 24, 2024Press Releases Japan’s Ministry of Health, Labour and Welfare Approves PADCEVTM (enfortumab vedotin) with KEYTRUDA® (pembrolizumab) for First-Lin...
https://www.astellas.com/en/newsEXPLORE ALL NEWS
https://www.astellas.com/en/aboutAbout us Astellas aims to stand on the forefront of healthcare change to turn innovative science into VALUE for patients. Read more
IMG-ALT About us
/en/innovation/rd-strategyR & D Strategy Astellas’ Focus Area approach supports our commitment to continuous innovation and the creation of innovative therapies that directly address ...
IMG-ALT R & D Strategy
/en/sustainabilitySustainability We are developing a sustainable society by leveraging Astellas’ strengths and capabilities. Read more
IMG-ALT Astellas and Sustainability
/en/partneringPartnering with Astellas We are actively seeking collaboration opportunities with external partners. Read More
/en/careers-at-astellasTextduplikat Careers
/en/investorsInvestor Relations Read More
IMG-ALT Investor Relations
https://www.linkedin.com/compa...Extern Subdomain Astellas Pharma’s official LinkedIn We share the latest information and topics. Follow us
IMG-ALT LinkedIn
/en/sustainability/respect-for...Modern Slavery Act 2015
/en/contact-r-and-d-programsSubdomain Contact for Potential Acquisition of Astellas’ R＆D programs.
https://www.linkedin.com/compa...Neues Fenster Extern Subdomain IMG-ALT Linkedin Logo
https://www.youtube.com/user/a...Neues Fenster Extern Subdomain IMG-ALT Youtube Logo
/en/global-linkedin-community-...Global LinkedIn Community Guidelines
A-TITLE Global LinkedIn Community Guidelines
/en/sitemapSITE MAP
/en/privacy-noticePRIVACY NOTICE
/en/cookies-policyCOOKIES POLICY
/en/accessibilityACCESSIBILITY
/en/terms-of-useTERMS OF USE
/en/contact-usCONTACT US
https://www4.bcportal.jp/astel...Extern Subdomain DISASTER INFORMATION FOR EMPLOYEES

Serverkonfiguration

HTTP-Weiterleitungen
(Extrem wichtig)
Die Seite leitet weiter auf "https://www.astellas.com/en/"
HTTP-Header
(Wichtig)
Es wird kein X-Powered HTTP-Header mitgesendet.
Der Webserver nutzt GZip zur komprimierten Übertragung der Webseite (HTML).
Performance
(Wenig wichtig)
Die Antwortzeit der HTML-Seite ist mit 1,86 Sekunden extrem langsam. Ein angepeiltes Ziel sollten 0,4 Sekunden sein. Suchmaschinen-Crawler können sonst Inhalte nicht so schnell aufnehmen und auch Besucher erwarten eine schnelle Webseite.
Die Dateigröße des HTML-Dokuments ist mit 85 kB in Ordnung.

HTTP-Header

NameWert
dateSun, 06 Oct 2024 06:42:04 GMT
content-typetext/html; charset=UTF-8
expiresSun, 19 Nov 1978 05:00:00 GMT
cache-controlmax-age=3600, public
varyCookie
x-drupal-dynamic-cacheUNCACHEABLE
content-languageen
x-content-type-optionsnosniff
x-frame-optionsSAMEORIGIN
last-modifiedFri, 04 Oct 2024 07:53:11 GMT
x-generatorDrupal 10 (https://www.drupal.org)
content-security-policydefault-src https: 'self' wss:; script-src https: 'unsafe-inline' 'unsafe-eval' 'self'; object-src 'self' sw4503.swcms.net; style-src https: 'unsafe-inline' 'self'; img-src https: data: www.astellas.com lh6.googleusercontent.com www.sto.ch 'self'; media-src * blob:; frame-src 'self' vars.hotjar.com sw4503.swcms.net www.google.com consentcdn.cookiebot.com www.googletagmanager.com www.youtube-nocookie.com www.youtube.com asia.tools.euroland.com player.vimeo.com login.doccheck.com w.soundcloud.com dreambroker.com td.doubleclick.net online.flippingbook.com; child-src 'self' blob: vars.hotjar.com sw4503.swcms.net www.google.com consentcdn.cookiebot.com www.googletagmanager.com www.youtube-nocookie.com www.youtube.com asia.tools.euroland.com player.vimeo.com login.doccheck.com w.soundcloud.com dreambroker.com td.doubleclick.net; font-src https: 'self' data:; report-uri /report-csp-violation
x-xss-protection1; mode=block
strict-transport-securitymax-age=1000
referrer-policystrict-origin-when-cross-origin
x-drupal-cacheMISS
x-request-idv-b428ce16-8225-11ef-af7e-0bf873a3b563
x-ah-environment01live
age2638
viavarnish
x-cacheHIT
x-cache-hits355
cf-cache-statusDYNAMIC
servercloudflare
cf-ray8ce3ab524bd071d3-FRA
content-encodinggzip
statuscode200
http_versionHTTP/2

Externe Faktoren

Die Seite wird von Wikipedia verlinkt.
Die Seite ist exzellent von anderen Webseiten verlinkt.
Die Seite hat Backlinks von 459 verweisenden Domains.
Die Seite hat insgesamt 4.064 Backlinks.
Die Seite hat Backlinks von 402 verschiedenen IP Adressen.

Links von Wikipedia

Mehr Links findest Du mit der Wikipedia-Suche

Robots.txt

#
# robots.txt
#
# This file is to prevent the crawling and indexing of certain parts
# of your site by web crawlers and spiders run by sites like Yahoo!
# and Google. By telling these "robots" where not to go on your site,
# you save bandwidth and server resources.
#
# This file will be ignored unless it is at the root of your host:
# Used:    http://example.com/robots.txt
# Ignored: http://example.com/site/robots.txt
#
# For more information about the robots.txt standard, see:
# http://www.robotstxt.org/robotstxt.html

User-agent: *
# CSS, JS, Images
Allow: /core/*.css$
Allow: /core/*.css?
Allow: /core/*.js$
Allow: /core/*.js?
Allow: /core/*.gif
Allow: /core/*.jpg
Allow: /core/*.jpeg
Allow: /core/*.png
Allow: /core/*.svg
Allow: /profiles/*.css$
Allow: /profiles/*.css?
Allow: /profiles/*.js$
Allow: /profiles/*.js?
Allow: /profiles/*.gif
Allow: /profiles/*.jpg
Allow: /profiles/*.jpeg
Allow: /profiles/*.png
Allow: /profiles/*.svg
# Directories
Disallow: /core/
Disallow: /profiles/
# Files
Disallow: /README.txt
Disallow: /web.config
Disallow: /sites/all/themes/astellas/js/astellas-popup.js
# Paths (clean URLs)
Disallow: /admin/
Disallow: /comment/reply/
Disallow: /filter/tips
Disallow: /node/add/
Disallow: /search/
Disallow: /user/register/
Disallow: /user/password/
Disallow: /user/login/
Disallow: /user/logout/
# Paths (no clean URLs)
Disallow: /index.php/admin/
Disallow: /index.php/comment/reply/
Disallow: /index.php/filter/tips
Disallow: /index.php/node/add/
Disallow: /index.php/search/
Disallow: /index.php/user/password/
Disallow: /index.php/user/register/
Disallow: /index.php/user/login/
Disallow: /index.php/user/logout/
# Disallow indexing of the entire SMPC backend
Disallow: /de/system/files/smpc/*
Disallow: /me/system/files/smpc/*
Disallow: /de/system/files/hcp/*
Disallow: /ch/system/files/hcp/*
Disallow: /ch/*/system/files/hcp/*
Disallow: /pl/system/files/privatefile/*
Disallow: /eu/system/files/c2p_astellas_sccs.0223_.pdf
Disallow: /system/files/astellas_sustainability_emailsignature_logo.jpg
Disallow: /system/files/astellas_sustainability_emailsignature_missionvision.jpg
Disallow: /me/system/files/pre-approved_global_congress_list_2023.pdf
Disallow: /br/system/files/mini-393186-xta-bra_xtandi_set_2023.pdf
Disallow: /en/system/files/privatefile/*
Disallow: /jp/system/files/privatefile/*
Disallow: /system/files/privatefile/*
Sitemap: https://www.astellas.com/sitemap.xml

Ähnliche Seiten

Suchvorschau

www.astellas.com
Astellas Home page | Astellas Pharma Inc.
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.

Wichtigste Suchbegriffe

Folgende Keywords wurden erkannt. Überprüfe die Optimierung dieser Keywords für Deine Seite.

KeywordErgebnisPrüfen
Astellas77%Check
Astellas Pharma73%Check
Astellas Pharma Inc70%Check
Inc60%Check
Astellas Global57%Check
Health46%Check
Products46%Check
innovative46%Check
Japan46%Check
VISION46%Check
Weitere Keywords anzeigen

Analysiere jetzt kostenlos bis zu 1.000 Unterseiten von astellas.com!

Kostenlos Testen
Die Nutzung des Basis Accounts ist zeitlich unbegrenzt möglich

Cookie Einstellungen

Wir verwenden Cookies, damit unsere Website funktioniert und auch für Analyse- und Werbezwecke. Du kannst optionale Cookies selbstverständlich auch deaktivieren, siehe die folgenden Links für weitere Informationen.

Impressum | Datenschutz

Diese Cookies werden für grundlegende Websitefunktionen benötigt.

Damit wir besser verstehen, wie Besucher unsere Website nutzen.

Damit wir für Dich passgenaue Angebote bereitstellen können.